Research programme: PDE3 inhibitors - Artesian Therapeutics

Drug Profile

Research programme: PDE3 inhibitors - Artesian Therapeutics

Alternative Names: 3QO4; ATI22-107; ATI24-214; heart failure therapeutics - Artesian Therapeutics; Type-3 phosphodiesterase inhibitors - Artesian Therapeutics; β-adrenoreceptor antagonists - Artesian Therapeutics

Latest Information Update: 03 Mar 2014

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Artesian Therapeutics
  • Class Small molecules
  • Mechanism of Action Type 3 cyclic nucleotide phosphodiesterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Heart failure

Most Recent Events

  • 28 Feb 2014 No development reported - Preclinical for Heart failure in USA (unspecified route)
  • 19 Apr 2006 This programme is still in active development
  • 27 Oct 2005 Artesian Therapeutics has been acquired by Cardiome Pharma
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top